Insider Transactions Reported by 24 Insiders of Arbutus Biopharma Corp

Symbol
ABUS on Nasdaq
Location
Warminster, PA

There are no Buy or Sell transactions made by insiders since 11 Mar 2025

Arbutus Biopharma Corp executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Matthew Gline Director, 10%+ Owner $127,536,218 24 Feb 2025
Michael J. McElhaugh Interim President & CEO, Director $5,443,224 14 Feb 2025
Michael J. Sofia Chief Scientific Officer $3,820,904 01 Feb 2024
William H. Collier President and CEO, Director $1,101,985 01 Feb 2023
DAVID C. HASTINGS Chief Financial Officer $820,172 14 Feb 2025
Karen Sims Chief Medical Officer $510,487 14 Feb 2025
J. Christopher Naftzger General Counsel and CCO $461,406 14 Feb 2025
Elizabeth Howard EVP, GC, Compliance $437,862 01 Feb 2023
Tuan Nguyen Chief Financial Officer $353,535 02 Feb 2026
KEITH S. MANCHESTER Director $169,972 14 Aug 2024
Lindsay Androski President and CEO, Director $134,680 02 Feb 2026
RICHARD C. HENRIQUES JR Director 23 May 2024
James R. Meyers Director 23 May 2024
DANIEL D. BURGESS Director 23 May 2024
Roger Sawhney Director 04 Aug 2025
Roivant Sciences Ltd. 10%+ Owner 18 Oct 2021
Frank Torti Director 23 May 2024
Robert A. Beardsley Director 18 Mar 2025
Tram Tran Director 25 May 2022
Gaston Picchio Chief Development Officer 20 Jan 2022
Melissa Rewolinski Director 23 May 2024
Joseph E. Bishop Director 24 Feb 2025
Andrew Cheng Director 03 Jun 2021
Anuj Hasija Director 18 Mar 2025

Recent Insider Transactions by Companies or Individuals for Arbutus Biopharma Corp

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.